Navigation Links
Perrigo Announces Conclusion of the FDA Re-Inspection
Date:4/12/2011

ALLEGAN, Mich., April 12, 2011 /PRNewswire/ -- Perrigo (Nasdaq: PRGO; TASE) today announced that the Detroit Office of the Food and Drug Administration (FDA) has concluded its re-inspection of Perrigo's Allegan facility. The FDA has informed Perrigo that, effective immediately, the Company has an acceptable regulatory status, such that any pending export license and ANDA applications from this facility will once again be eligible for review and approval.

Perrigo's Chairman and CEO Joseph C. Papa stated, "On behalf of Perrigo, I want to thank the FDA Detroit District for making the re-inspection of our facilities a priority and for working cooperatively with us to resolve the issues previously raised in the Warning Letter. We are convinced that this process has made us a better company by enhancing the quality of our affordable healthcare products for our customers."  

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and ot
'/>"/>

SOURCE Perrigo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Perrigo Company to Present at the Barclays Capital 2011 Global Health Care Conference
2. Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter
3. Perrigo Company to Present at the Citi 2011 Global Health Care Conference
4. Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma
5. Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix for Store Brand Blood Glucose Monitoring Products
6. Perrigo Announces Settlement of Rogaine® Foam Patent Litigation
7. Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance
8. Perrigo Company Announces Quarterly Dividend
9. Perrigo to Acquire Assets of Paddock Labs for $540 Million
10. Perrigo Company Will Release Second Quarter Fiscal 2011 Results on February 1, 2011
11. Perrigo Company to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: ... Office (USPTO) has issued a key patent covering ... vaccine targeting six tumor antigens that are commonly ... No. 8,871,211, which issued October 28, 2014, include ... dendritic cell composition comprising peptide epitopes of the ...
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
(Date:12/15/2014)... December 15, 2014 BerGenBio AS, ... aggressive drug resistant cancers, today announces that it has ... placing from new and existing investors. BerGenBio ... the development of its pipeline of innovative cancer therapeutics, ... lead drug candidate, BGB324, a first-in-class selective Axl kinase ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2BerGenBio Completes NOK90 Million Fundraising 2
... DIEGO, March 10, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... today announced financial results for the three months and year ended ... 31, 2010 For the three months ended December ... $0.24 per share, as compared to a net loss of $15.0 ...
... 2011 Dendreon Corporation (Nasdaq: DNDN ) ... (FDA) approved the remainder of its New Jersey manufacturing ... of PROVENGE® (sipuleucel-T) to help meet the needs of ... (hormone refractory) prostate cancer.   Last April, ...
Cached Medicine Technology:Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 2Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 3Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 4Dendreon Expands Launch of PROVENGE 2Dendreon Expands Launch of PROVENGE 3Dendreon Expands Launch of PROVENGE 4Dendreon Expands Launch of PROVENGE 5
(Date:12/19/2014)... December 19, 2014 Slone ... diagnostic, personalized medicine, healthcare information technology, and laboratory ... position of Chief Operating Officer. The announcement comes ... marked by a strengthened presence in Boston and ... "Leslie lives and breathes the client experience," said ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Being in good ... researchers report. They looked at data from more than ... who underwent treadmill tests between 1991 and 2009. Those ... chance of having high blood pressure at the start of ... with high levels of fitness. Of the more than ...
(Date:12/19/2014)... -- Traveling through the same U.S. airport gate, one ... within a four-hour time span, illustrating just how easily ... "The exposures in this report were not prolonged and ... highlighting the fact that measles is highly contagious," wrote ... specialist at the U.S. Centers for Disease Control and ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Unidesk ... Osteopathic Medicine (ACOM), which welcomed its inaugural class ... Infrastructure (VDI) to seamlessly support bring your own ... and teaching – experience. The solution, comprised of ... , Dell server and storage infrastructure ...
(Date:12/17/2014)... Miami, FL (PRWEB) December 17, 2014 ... has not been able to eradicate the head louse ... and hassle for parents. Each year between six and ... Lice Troopers, the Miami-based lice removal treatment company comes ... safe, non-toxic and environmentally friendly. With its track record ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... 28 Dr. Eaton E.,Lattman, currently Dean of Research ... and Sciences at Johns Hopkins University (JHU), has,been appointed ... Research Institute. Lattman will assume the,position on July 1, ... has degrees from Harvard and JHU and at JHU ...
... medications longer, study finds , , FRIDAY, March 28 (HealthDay ... than the older drug haloperidol in treating a first ... it appears that more patients prefer the newer drugs ... haloperidol, the study authors said. , "When we compared ...
... Raleigh County League of,Democratic Women will conduct a mock ... Clinton and Barack Obama., "We,re not expecting the ... each one will be represented by two local,volunteers supporting ... be held at 6 p.m. Tuesday at the Raleigh ...
... using whole body 16 multi-detector CT (MDCT); theres no need ... recent study conducted by researchers at the University of Maryland ... in Baltimore, MD. The study showed that whole body MDCT ... In the past, blunt trauma patients would undergo whole-body MDCT ...
... from Boston University School of Medicine (BUSM) and ... found that decreased sexual satisfaction in postmenopausal women, ... study appears in the April 2008 issue of ... dysfunction is a common condition and has been ...
... to try technology like sensors,to detect falls and ... perception, and technical issues remain challenges, WASHINGTON, ... so they can age safely in their home. ... the challenges of caregiving.,Concerns such as cost to ...
Cached Medicine News:Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 3Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3Health News:Whole body MDCT just as 'good' as neck MDCT angiography in diagnosing head and neck injuries 2Health News:Decreased sexual satisfaction is not associated with cardiovascular disease in postmenopausal women 2Health News:Older People Want to Use Technology to Help Them Remain at Home 2Health News:Older People Want to Use Technology to Help Them Remain at Home 3Health News:Older People Want to Use Technology to Help Them Remain at Home 4
8 mm S Graftech cervical spacer....
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
... system for procedures in the ... system features a broad selection ... for many Craniomaxillofacial procedures. 1.5 ... used predominately in the less ...
... Fixation Systems incorporate a great number ... surgeons and surgical staff. Additionally, the ... either shaped on the spot or, ... cut, bent and shaped implant utilizing ...
Medicine Products: